Skip to main content
Journal cover image

Pharmacokinetic interactions between buprenorphine and antiretroviral medications.

Publication ,  Journal Article
Bruce, RD; McCance-Katz, E; Kharasch, ED; Moody, DE; Morse, GD
Published in: Clin Infect Dis
December 15, 2006

Buprenorphine is used for the treatment of opioid dependence. As the number of persons receiving buprenorphine treatment and antiretroviral therapy continues to grow, so too does the existence and clinical impact of drug interactions between buprenorphine and medications for treating human immunodeficiency virus (HIV) infection. Awareness that such interactions exist may deter some patients and physicians from initiating potentially lifesaving therapy or lead to complications among patients whose treatment is already under way. Complications include nonadherence to antiretroviral therapy and the development of viral resistance. Illicit drug use is a frequent consequence of adverse drug effects experienced by injection drug users. The occurrence of unrecognized drug interactions can lead to unsuccessful therapy for HIV infection and the treatment of substance dependence. The present review is organized to provide a working background of buprenorphine pharmacology. Review of the current state of knowledge regarding specific interactions between buprenorphine and antiretrovirals is followed by a review of the clinical applicability of these interactions.

Duke Scholars

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

December 15, 2006

Volume

43 Suppl 4

Start / End Page

S216 / S223

Location

United States

Related Subject Headings

  • Treatment Refusal
  • Sensitivity and Specificity
  • Risk Factors
  • Opioid-Related Disorders
  • Narcotic Antagonists
  • Microbiology
  • Male
  • In Vitro Techniques
  • Humans
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bruce, R. D., McCance-Katz, E., Kharasch, E. D., Moody, D. E., & Morse, G. D. (2006). Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis, 43 Suppl 4, S216–S223. https://doi.org/10.1086/508186
Bruce, R Douglas, Elinore McCance-Katz, Evan D. Kharasch, David E. Moody, and Gene D. Morse. “Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Clin Infect Dis 43 Suppl 4 (December 15, 2006): S216–23. https://doi.org/10.1086/508186.
Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S216–23.
Bruce, R. Douglas, et al. “Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Clin Infect Dis, vol. 43 Suppl 4, Dec. 2006, pp. S216–23. Pubmed, doi:10.1086/508186.
Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S216–S223.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

December 15, 2006

Volume

43 Suppl 4

Start / End Page

S216 / S223

Location

United States

Related Subject Headings

  • Treatment Refusal
  • Sensitivity and Specificity
  • Risk Factors
  • Opioid-Related Disorders
  • Narcotic Antagonists
  • Microbiology
  • Male
  • In Vitro Techniques
  • Humans
  • HIV Infections